OraSure selloff looks overdone, says Canaccord. Canaccord analyst Mark Massaro noted OraSure shares traded down following its Q1 beat. The analyst thinks the weakness is overblown as he notes molecular collections grew revenues 72% year-over-year and continues to win new business in a huge market. He also noted the leadership changes and the ongoing strategic review. Massaro maintained his Buy rating and lowered his price target to $20 from $24 on OraSure shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.